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Huntington’s disease (HD) is a devastating neurodegenerative disorder which is inherited in an autosomal dom-
inant manner. HD is caused by a trinucleotide CAG repeat expansion that encodes a polyglutamine stretch in
thehuntingtin (HTT)protein.MutantHTTexpression leads toamyriadofcellulardysfunctionsculminating inneur-
onal loss and consequent motor, cognitive and psychiatric disturbances in HD patients. The length of the CAG
repeat is inversely correlated with age of onset (AO) in HD patients, while environmental and genetic factors
can further modulate this parameter. Here, we explored whether the recently described copy-number variation
(CNV) of the gene SLC2A3—which encodes the neuronal glucose transporter GLUT3—could modulate AO in
HD. Strikingly, we found that increased dosage of SLC2A3 delayed AO in an HD cohort of 987 individuals, and
that this correlated with increased levels of GLUT3 in HD patient cells. To our knowledge this is the first time
thatCNVofacandidategenehasbeenfoundtomodulateHDpathogenesis.Furthermore,wefoundthat increasing
dosage ofGlut1—theDrosophilamelanogasterhomologue of this glucose transporter—ameliorated HD-relevant
phenotypes in fruit flies, including neurodegeneration and life expectancy. As alterations in glucose metabolism
have been implicated in HD pathogenesis, this study may have important therapeutic relevance for HD.
INTRODUCTION
Huntington’s disease (HD, OMIM #143100) is a fatal autosomal
dominant neurodegenerative disorder characterized by motor,
psychiatric and cognitive dysfunction, with a mean age of
onset (AO) of40–50 years (1). The polymorphism underlying
the disease is a CAG trinucleotide repeat in the huntingtin (HTT)
gene, which leads to disease above a critical threshold of 36
repeats (2). The length of this repeat expansion accounts for up
to 70% of the variability of AO, with which it is inversely corre-
lated. Additional genetic factors are likely to explain a large
proportion of the remaining variability of AO, and thus have
the potential to modulate AO and other symptoms in HD (3).
The identification of genetic modifier loci contributes to our
understanding of HD pathogenesis and may ultimately facilitate
the development of novel therapeutic interventions for this dev-
astating disorder.
Aberrant glucose metabolism of the central nervous system
(CNS) is a typical hallmark for several brain diseases. In the
context of HD, 18F-fluorodeoxyglucose positron emission tom-
ography scanning has revealed a loss of glucose uptake in the
striatum and cortex of patients, remarkably before the onset of
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clinical symptoms of the disease (4). In asymptomatic HD gene
carriers striatal metabolism is significantly decreased in the
absence of atrophy, and the progression rate of HD shows a
better correlation with the detected hypometabolism independ-
ent of CAG length (4–9). Interestingly, a 5-year follow-up
study on asymptomatic HD gene carriers found that the
caudate glucose metabolism was significantly decreased in
patients that became symptomatic in the course of the study,
and this change was not correlated with the CAG mutation
length (10). In the same study, considering the relative caudate
glucose metabolism along with CAG mutation length increases
the regression coefficient for prediction of AO, indicating that
glucose metabolism is a good predictor of disease onset
(10,11). The role of the glucose metabolism in HD has also
been demonstrated in several HD model studies. R6/2 HD
model mice show an early and progressive metabolic impair-
ment, which is significantly associated with lower glucose
uptake, and is independent of cell loss (12). Furthermore,
primary cortical neurones derived from HD140Q knock-in
mice exhibit reduced levels of glucose uptake (13). Increasing
glucose entry in glia was also found to reduce glia-induced path-
ology in fly models of HD (14). These studies suggest that dys-
function of glucose metabolism contributes to HD
pathogenesis, and that its normalization may have therapeutic
relevance in this disorder.
Glucose transport in humans is mediated either by active
sodium–glucose co-transporters or by facilitative glucose trans-
porters (GLUTs) (15). Several GLUT isoforms are expressed in
the CNS, with GLUT1 (encoded by SLC2A1) and GLUT3
(SLC2A3) being the main transporters responsible for glucose
uptake in the brain. GLUT1 is predominantly found at the
blood–brain barrier while GLUT3 is primarily expressed in neu-
rones, and shows higher glucose affinity and faster transport
compared with GLUT1, characteristics that suit a high energy
demand transporter (16).
While the homozygous knockout ofSLC2A3 causes embryon-
ic lethality in mice, heterozygotes show abnormal spatial learn-
ing, social behaviour and working memory, as well as
electroencephalographic seizures, although their motor abilities
and coordination are normal (17). SLC2A3 heterozygote mice
show no differences in glucose uptake in the brain, suggesting
that GLUT3 levels are not limiting in this particular model
system (18). However, under hypoxic-ischaemia brain injury,
SLC2A3 heterozygote mice demonstrate spontaneous seizures
and undergo enhanced brain apoptosis/necrosis, while control
wild-type mice do not, suggesting that a difference in phenotype
becomes more pronounced under stress (19).
In humans (and other primates), the SLC2A3 gene is in a
129 kb region that has been tandemly duplicated to form
SLC2A14, a testis-specific GLUT gene. Subsequent non-allelic
homologous recombination events within the human population
have resulted in an SLC2A3 deletion allele and an SLC2A3 dupli-
cation allele present at low frequencies in the European popula-
tion (20). Therefore, copy-number variation (CNV) of SLC2A3
has been observed, between one copy (heterozygous deletion)
and three copies (heterozygous duplication).
In this study, we adopted a candidate gene approach, hypothe-
sizing that CNV of a neuronal GLUT could influence HD AO.
We reasoned that a decreased dosage of GLUT3 would make
HD patients less capable of coping with situations where
higher glucose demand is required, and thus lead to earlier
disease onset. By extension, additional copies of SLC2A3 may
confer protection to patients, and lead to HD manifesting later
in life. We found that increased dosage of SLC2A3 was asso-
ciated with an increase in GLUT3 in HD patients and a delay
in AO in HD patients. Furthermore, we found that increased
dosage ofGlut1, the fruit fly orthologue of SLC2A3, is protective
in HD model flies, underscoring the importance of GLUT3 in HD
pathogenesis and potential future therapeutic interventions.
RESULTS
SLC2A3 copy number modifies AO in HD
To investigate whether SLC2A3 CNV might influence HD
pathogenesis, we choose to genotype 987 HD patients for this
genomic variation (Fig. 1). Diploid copy-number frequencies
were determined (Table 1), and the duplication genotype fre-
quencies (2, 3 and 4 copies) were found to be in Hardy–Wein-
berg equilibrium (x2 ¼ 1.16, P ¼ 0.28). To assess the effect of
copy number on AO, we initially plotted the distribution of
CAG length and AO, stratified by SLC2A3 copy number
(Fig. 2). There is little obvious effect of the one copy genotype,
with one copy individuals either side of the regression curve, but
there is a noticeable difference in the distribution of three and
Figure 1. Scatterplot and histograms of raw PRT data. Raw duplicate PRT ratios
for the 987 samples genotyped are shown. Points are distinguished to reflect the
final SLC2A3 copy number call, as shown in the legend. Summary histograms of
the data are also shown.
Table 1. Diploid copy number frequencies in the HD cohort
SLC2A3 copy number Number
1 Copy 5
2 Copies 945
3 Copies 36
4 Copies 1
Total 987
3130 Human Molecular Genetics, 2014, Vol. 23, No. 12
Downloaded from https://academic.oup.com/hmg/article-abstract/23/12/3129/696124
by CNR user
on 13 June 2018
four copy individuals, where 25/36 (69%) are above the regres-
sion curve, and therefore have a later AO than is predicted by
CAG length alone.
We formally tested this by constructing a generalized linear
model incorporating CAG length and SLC2A3 copy number,
which showed a significant positive association of SLC2A3
copy number with log2AO (P ¼ 0.022). This association is not
dependent on the threshold calling of copy number between
one and two copies (Table 2). Indeed altering the threshold, so
that fewer samples are called at one copy improves the signifi-
cance level slightly to 0.015. The modest significance value
reflects the small overall effect on AO in the HD population,
and this is due to the low frequency of the deletion (0.25%)
and duplication alleles (1.9%). Indeed, the effect on individual
AO is pronounced, using the regression model the increase in
AO per copy can be estimated at 3 years [95% confidence
interval (CI) 0.4–5.67, Table 3].
CNV of SLC2A3 in HD patient lymphoblastoid
cells alters protein levels of GLUT3
We then asked whether SLC2A3 copy number affected GLUT3
protein levels by a gene dosage effect. Although predominantly
expressed in neurones, SLC2A3 is expressed in other tissues and
also in leukocytes, including B cells (21). Unfortunately, neur-
onal tissue or cell lines from patients with different SLC2A3
copy numbers were not available. However, lymphoblastoid
cell lines (LCLs), derived from Epstein–Barr virus-immortal-
ization of B cells from peripheral blood, were available, and
therefore chosen as a model to investigate the gene dosage
effect of SLC2A3.
For each ofSLC2A3 copy numbers 1, 2 and 3, five LB cell lines
were grown and total protein extracted. Semi-quantitative im-
munoblotting was used to estimate the amount of GLUT3
protein in the cells, relative to levels of tubulin as a control.
For each cell line, measurements from at least four replicate
blots were analysed (two representative blots are shown in
Fig. 3). Considerable variation exists within each copy number
category, both at the biological level between cell lines from dif-
ferent patients with the same copy number, and at the technical
level due to the semi-quantitative nature of the assay. To fully
allow for this variation, we employed a mixed effects linear
regression model to explore the association between GLUT3
protein level and SLC2A3 copy number. Pairwise comparison
showed a significantly higher expression level in three copy indi-
viduals compared with two copy individuals (P, 0.001) but not
in two copy individuals compared with one copy individuals
(P ¼ 0.28). This is consistent with our observation from the
HD patient cohort that three SLC2A3 copies contributes most
to the neuroprotective effect, but this could also be due to a
lack of power in either experiment. Indeed, a significant linear
correlation between copy number and GLUT3 expression level
was seen (b ¼ 0.09, P ¼ 0.02).
Figure 2.CAG length and AO of HD cohort, stratified by SLC2A3 copy number.
Scatterplots and histograms are shown for patients stratified by SLC2A3 copy
number. The exponential best fit line is shown, reflecting the linear best fit on log-
transformedAO data. (A) Patients withSLC2A3copy number of two. (B) Patients
with SLC2A3 copy number of one. (C) Patients with SLC2A3 copy number of
three.
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Altered dosage of the GLUT3 orthologue in Drosophila
modulates HD phenotypes
To recapitulate the effect of SLC2A3 CNV on HD, we next
turned to an established and well-characterized Drosophila
model of HD (22) which we have extensively employed in
other studies (23–28). This model uses the bitransgenic UAS/
GAL4 system to drive pan-neuronal expression of an exon 1
mutant HTT fragment (HTT93Q) using the elavGAL4 driver,
and yields several disease-relevant phenotypes, including de-
generation of rhabdomeres (photoreceptor neurones), reduced
lifespan, and impaired eclosion of adult flies from the pupal
case. To identify the orthologue of the human GLUT3 protein,
we searched two databases for predicted GLUTs in Drosophila.
Seven candidate protein sequences were identified, which were
aligned and a phylogenetic tree constructed using a maximum-
likelihood approach (Fig. 4). The Drosophila protein GLUT1
is the clear orthologue of human GLUT3, with an amino acid
identity of 46%, and is its functional homologue since it is the
neurone-specific facilitative GLUT in Drosophila.
We thus interrogated GLUT1 function in this fly model of HD
via several approaches. First, we confirmed that Glut1 expres-
sion levels were modulated in these transgenic lines using quan-
titative real-time polymerase chain reaction (QPCR) analysis
(Supplementary Material, Fig. S1). We found that RNAi knock-
down reduced Glut1 mRNA expression by 35% (P , 0.05),
while overexpressing Glut1 using the Glut1d05758 overexpres-
sion line significantly increased expression levels by 78%
(P, 1 × 1024). Having validated the specificity of the trans-
genic lines, we next investigated the effects of GLUT1 manipu-
lation on disease-relevant phenotypes in Htt93Q flies. First, we
employed a robust readout of neurodegeneration—the degener-
ation of the photoreceptor neurones (rhabdomeres) (Fig. 5A and
B). We find that either a loss-of-function mutation in the Glut1
gene (Glut117J), or RNAi knockdown of this gene, enhances
rhabdomere loss in Htt93Q flies, though only in the case of
RNAi is the effect significant. We also find that Glut1 overex-
pression—via the Glut1d05758 allele (29)—significantly
rescues this neurodegeneration (Fig. 5A). Strikingly, these
results parallel the HD AO observations above—increased
dosage of Glut1 expression is correlated with amelioration of
disease phenotypes.
We next asked whetherGlut1 dosage in HD flies could modu-
late general viability and health phenotypes in these animals by
scoring eclosion frequency and lifespan. Htt93Q Glut117J flies
exhibit reduced eclosion frequency compared with Htt93Q
(P , 0.05) or Htt93Q Glut1-overexpressing flies (P, 0.01)
(Fig. 5C), and that Htt93Q Glut1-overexpressing flies have
increased eclosion versus Htt93Q flies, though this is not signifi-
cant. We also observed that Htt93Q Glut1 RNAi flies have a
significantly shorter lifespan compared with Htt93Q flies (P,
0.05) (Fig. 5D), while Glut1 overexpression has no effect on
this metric (data not shown). In total, these data support our
neurodegeneration data, and suggest that increased dosage of
Glut1 ameliorates disease phenotypes in HD flies.
DISCUSSION
Taken together, our data from human genetic analysis, molecu-
lar biology and aDrosophilaHD model strongly support the hy-
pothesis that increased dosage of SLC2A3 ameliorates HD
phenotypes, which may have important therapeutic ramifica-
tions. To our knowledge this is the first example indicating that
a CNV event can be a genetic modifier of AO in HD. While it
is known that gene deletion and duplication can affect neurode-
generation, in the past this has been limited to a small subset of a
complex neurodegenerative disorders that show Mendelian in-
heritance, for example the triplication of a-synuclein or large
deletions of the Parkin gene causing Parkinson’s disease
(30,31). The role of CNV with alleles at polymorphic frequen-
cies in modifying the susceptibility to neurodegenerative
disease remains unclear.
Many other studies have identified possible genetic variants
that appear to affect the AO in HD patients; the most frequently
identified variants are single nucleotide polymorphisms (SNPs)
often of uncertain functional effect (32). Indeed, many early
studies showing putative effects of SNPs on HD AO have not
been replicated by larger studies, suggesting that most of the
initial reports, often on small patient cohorts, are false positives
(33,34). In this study, we analysed almost 1000 patients from the
REGISTRY investigators of the European Huntington’s Disease
Network (EHDN) for a rare CNV in the SLC2A3 gene. The asso-
ciation has a modest significance (P ¼ 0.022) reflecting the low
frequency of the deletion and duplication alleles (0.25 and 1.9%,
respectively), but, importantly, carrying a duplication allele
(3.6% of patients in our study) delays the AO of clinical symp-
toms of HD by 3 years. The low frequency of both duplication
and deletion alleles of SLC2A3 poses a particular challenge in
genetic association studies. In this study, despite a strong size
of effect attributed to SLC2A3 CNV, the statistical support for
such an effect is modest. This has two consequences. First, it
illustrates the importance, if feasible, of recapitulating the
CNV in a model system, to provide further biological support
for a posited effect. Second, it emphasizes the importance of
large patient cohorts in identifying and confirming genetic modi-
fier effects.
A recent study identified the SLC2A3 CNV, with allele fre-
quencies of the deletion and duplication consistent with our
observed frequencies: 1% deletion frequency and 2.2% duplica-
tion frequency in a Swedish population (20). A replicated case–
control study showed deletion of SLC2A3 was strongly protect-
ive against rheumatoid arthritis (odds ratio 0.442), and it was
suggested that the role of GLUT3 as a GLUT in B cells and chon-
drocytes may provide a biological basis for this observation. The
Table 2. Threshold for calling SLC2A3 1 copy patients and significance of
association
PRT threshold for calling 1 copy 0.6 0.65 0.7 0.75
Number of 1 copy patients called 3 5 5 7
P-value 0.015 0.022 0.022 0.019
Table 3. Effect of SLC2A3 copy number on AO
Mean (95% CI) (years) P-value
Effect per extra CAG repeat 22.34 (22.24 to 22.45) ,5 × 1026
Effect per extra copy of SLC2A3 2.98 (0.40–5.67) 0.022
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authors also showed that the CNV alleles were not effectively
tagged by flanking SNPs with a minor allele frequency .5%.
These data suggest that disease effects of CNV at this locus are
invisible to SNP-based genome-wide association studies, at
least at the usual current study sizes. Our studies suggest that
HD progression could be affected by GLUT3 expression level,
and functionality as in neurones glucose uptake is mainly de-
pendent on this transporter. Indeed, a post-mortem brain study
found a significant reduction in GLUT3 levels in the caudate
of Grades 1 and 3 HD brain, but not in the cortex (35).
Our observations highlight the importance of neuronal
glucose metabolism in neurodegenerative disease and suggest
novel candidate therapeutic avenues. It will be now critical to
study the potential for pharmacological modulation of GLUT3
function or expression, as well as uncovering more general
approaches for increasing glucose import into neuronal
Figure3.Relationship betweenSLC2A3 copy number and GLUT3 protein levels in LCLs from HD patients. (A) Two representative western blots of protein extracted
from 20 LCLs from HD patients. In each example, the upper panel shows detection of GLUT3 protein revealed by anti-GLUT3 antibody, and the lower panel shows
detection of tubulin as a loading control. (B) Graph summarizing data from quantification of repeated western blot experiments. Individual points represent individual
measurements, with point shape reflecting SLC2A3 copy number of the cell line (circle ¼ 1 copy, triangle ¼ 2 copies, cross ¼ 3 copies). Boxes show median and
interquartile range. GLUT3 protein level is shown as a value relative to the level of tubulin detected in the same gel lane.
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populations sensitive to degeneration or dysfunction in suscep-
tible regions of the HD brain. While our study is limited to
HD, we believe that these findings will have direct relevance
to the pathogenesis of other neurodegenerative disorders, and
may ultimately inform future therapeutic strategies for a broad
variety of these related diseases.
MATERIALS AND METHODS
HD patient DNA samples and SLC2A3 genotyping
The study cohort comprised of 987 unrelated individuals of
European ancestry with manifest HD enrolled in the EHDN
‘REGISTRY’ study (36). ‘REGISTRY’ is a multi-centre, multi-
national observational study, which catalogues data in a wide
range of the European HD population (http://www.euro-hd.
net/html/registry last accessed 25 January 2014). Experienced
investigators estimate the age at onset based on the integration
of data from the patient’s history, collateral history of family
or carers and the examination of the patient. Manifest HD was
defined as carrying the HTT CAG repeat expansion mutation
(≥36) and having a motor score with a diagnostic confidence
of four on the UHDRS motor scale (37). Clinical data on AO
and mutant CAG repeat size were provided. In our cohort, AO
was defined as the AO of any symptom of HD. In most patients
(620), these were motor symptoms, with psychiatric symptoms
accounting for the second largest grouping (169).
SLC2A3 copy number was typed on these individuals using a
paralogue ratio test (PRT), which is a form of quantitative PCR
that uses the same primer pair for test and reference amplicons
(38). The PRT assay, termed ‘P1’, was developed and extensive-
ly validated previously (20). We used a fluorescently labelled
primer to allow electrophoresis and subsequent fluorescent de-
tection of products using an Applied Biosystems ABI 3130XL
capillary electrophoresis machine. Each sample was typed
twice, an estimate of the ratio of test:reference peak areas
made and repeated if the coefficient of variation of the two
values was .0.15. The raw results of the duplicate measure-
ments are shown in Figure 1.
We called integer copy number, blind to clinical status orHTT
CAG repeat number, using the PRT ratio thresholds derived by
manual inspection of the data clustering. The single outlier
with a high PRT ratio could either be a homozygous duplication
(SLC2A3 copy number 4) or be a heterozygous deletion of the
reference region, but following confirmation of presence of the
duplication allele by a breakpoint-specific PCR (39) this was
called as a SLC2A3 four copy individual.
HD lymphoblastoid cell culture and immunoblotting
Lymphoblastoid cell lines (LCLs) were established from periph-
eral blood of HD patients by BioRep (Milan, Italy) for the EHDN.
Five LCLs were selected from each group of individuals (carrying
1, 2 and 3 copy number of SLC2A3), which were previously gen-
otyped in our study. The cell lines were maintained at 0.5–1 ×
106 cell/ml concentration in RPMI 1640 with GlutaMAXTM
(Life Technologies) with 10% fetal bovine serum, 100 U/ml peni-
cillin and 100 mg/ml streptomycin, at 378C in a 95% air/5% CO2
atmosphere. Cell pellets containing 20× 106cells were washed
two times with sterile phosphate buffered saline and then lysed
in 200 ml of lysis buffer (40). Lysates were centrifuged at 13
000 revolutions per minute for 10 min at 48C. Supernatants
were collected, and protein concentration was determined by
the Bradford method. Samples were stored at 2808C until ana-
lysed. Ten micrograms of total cell lysate were separated on a
10% sodium dodecyl sulphate polyacrylamide gel and transferred
to a polyvinylidene difluoride membrane. Incubation with
primary antibodies was overnight at 48C, using polyclonal
rabbit anti-GLUT3 antibody (1:4000; ab15311, Abcam) or
mouse anti-tubulin (1:1000; sc-8035, Santa Cruz Biotechnology).
Blots were developed using horseradish peroxidase-conjugated
secondary antibodies (1:10 000; PI-1000 anti-rabbit, Vector La-
boratories, and 1:10 000; PI-2000 anti-mouse, Vector Laborator-
ies) and the ECL system (SuperSignal West Dura Extended
Duration Substrate, Thermo Scientific). Semi-quantitative
analysis of immunoblot data was assessed using ImageJ software
(National Institutes of Health).
Figure 4.Phylogenetic tree of human GLUT3 protein (HsGLUT3) and candidate homologues inDrosophila. Numbers at nodes represent percentage of 500 bootstrap
trees supporting that node. Scale bar represents 0.2 amino acid substitutions per site. ScHXT2 is a hexose transporter fromS. cerevisiae and is considered the out-group.
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Identification of GLUT3 Drosophila homologue
Candidate Drosophila homologues of human GLUT3 were
identified by a search of UniProt and by blastp analysis of Dros-
ophila protein sequences in the non-redundant database. The
protein sequence HXR2 GLUT of Saccharomyces cerevisiae
was used as an out-group. Clustal Omega was used to align the
amino acid sequences, and MEGA5.2 (41) was used to generate
a maximum-likelihood tree, with 500 bootstrap replicates, the
Jones–Taylor–Thornton model of protein evolution (42), with
uniform rates across sites.
Drosophila stocks
Flies were raised on standard maize media, in a 12 h light, 12 h
dark cycle at 258C. The Glut1d05758 and Glut117J alleles and
elav-GAL4 (c155) driver stocks were obtained from the Bloo-
mington Stock Center (IN, USA). The Glut1 RNAi transgenic
line (108683) was obtained from the Vienna Drosophila RNAi
Centre (Austria). The w;+; UASHttQ93 exon1 line (43) was a
gift from J.L. Marsh and L. Thompson (University of
California, Irvine).
Pseudopupil analysis
The number of visible rhabdomeres per ommatidium was scored
from 40 to 100 ommatidia per fruit fly, with 8–15 flies examined
per genotype at Days 1 and 7 post-eclosion. Heads were removed
from the body and fixed to a microscope slide using fingernail
polish. Rhabdomeres were visualized at 500× magnification
using either a Nikon Optiphot-2 or an Olympus BH2 microscope.
Eclosion and longevity analyses
The eclosion rate was scored from 10 independent crosses
between five males carrying the elav-GAL4 driver and five
Figure5. Increased pan-neuronal dosage ofGlut1 inDrosophila improves HD phenotypes. (A) Htt93QGlut117J flies enhanced rhabdomere loss in Day 1 Htt93Q flies,
while Glut1 overexpression protected against neurones loss at Days 1 and 7. n ¼ 8–15. Statistical comparisons by ANOVA and post hoc test (∗∗P-value
, 0.01; ∗∗∗P-value, 0.001). Mean+SEM. (B) Quantification of rhabdomeres per ommatidium in Htt93Q and Htt93Q Glut1 RNAi flies at Days 1 and 7 after
eclosion. N ¼ 9–15 flies per genotype. Statistical comparisons by ANOVA and post hoc tests versus Htt93Q flies (∗P-value, 0.05; ∗∗∗P-value, 0.001).
Mean+SEM. (C) Htt93Q Glut117J flies showed a decreased adult emergence from the pupal case compared with Htt93Q and Htt93Q Glut1 OE flies. n ≥ 1000
progeny for each cross. Statistical comparisons by ANOVA and post hoc test (∗P-value, 0.05; ∗∗P-value, 0.01). Mean+SEM (D) Glut1 down-regulation
decreased median survival of adult HD flies. The number of flies surviving from each cohort was determined every day. n ¼ 100 animals per genotype. Statistical
analysis by Kaplan–Meier survival curve analysis with log-rank test (∗P-value, 0.05).
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virgin females carrying the transgenes of interest. The numbers
of males and females were counted every day until all of the
viable F1 progeny had enclosed. The adult emergence percent-
age was calculated as a ratio between female and all progeny,
where the females expressed the transgene of interest
(Htt93Q). Lifespan was assessed on 100 female flies for
each strain analysed. Flies were collected within 24 h of emer-
gence, divided into groups of 10 per vial and kept at 258C.
According to the genotype of interest, the flies were transferred
daily or every 3-4 days in a new tube and the dead flies were
scored.
Statistics
Association of SLC2A3 copy number with HD AO was tested by
generating a generalized linear model using SPSS 20 (IBM), with
CAG as a continuous predictor, SLC2A3 copy number as an
ordinal predictor and log2AO as the continuous response variable,
using Wald Type III analysis of variance (ANOVA) statistics. As-
sociation of SLC2A3 copy number with protein levels was tested
by a mixed effects linear model, after confirmation that the distri-
bution of GLUT3 levels did not depart from a Gaussian distribu-
tion (P ¼ 0.17, Shapiro–Wilks test). Statistical analyses of the
Drosophila data were carried out using ANOVA where
applicable with Newman–Keuls post hoc tests using Statistica
(StatSoft Ltd.) or Prism 6 (GraphPad Software). For longevity
analysis, survival curves were generated, and data were analysed
by using the Kaplan–Meier method and statistical significance
ascertained using log-rank statistics software (GraphPad
Software).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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